GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

Britain's GSK will buy RAPT Therapeutics for $2.2 billion, adding global rights to the U.S. firm's experimental food allergy ...

Britain's GSK has agreed to buy RAPT Therapeutics for $2.2 billion, accessing the U.S. biotech's experimental drug to treat ...

GSK plc to acquire RAPT Therapeutics Inc. for $58.00 per share, with an estimated upfront investment of $1.9 billion.

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

GSK acquires Rapt Therapeutics for $2.2B. Stock surges 65% as pharma giant gains access to phase 2b food allergy treatment ...

GlaxoSmithKline (GSK) has agreed to acquire Rapt Therapeutics for $2.2 billion, the companies said today, in a deal intended to bolster the buyer’s pipeline with Rapt’s ozureprubart (RPT904), a ...

GSK will buy RAPT Therapeutics for $2.2 billion, ‍the British drugmaker said on Tuesday, expanding its respiratory, ...

GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...

Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share at closing for an estimated ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.